May 9, 2025
- First Oxbryta Trial Scheduled: The first trial in the Oxbryta litigation has been scheduled for August 16, 2027. The trial will address allegations that Pfizer knowingly marketed a defective sickle cell drug while downplaying the risks of serious complications.
April 16, 2025
- New Lawsuit Filed Alleging Wrongful Death: A California woman has filed a lawsuit against hospital systems and pharmaceutical corporations, including Pfizer, alleging that medical malpractice and the defective design of Oxbryta contributed to her husband's death from complications of sickle cell disease. The lawsuit cites Pfizer's later market withdrawal of Oxbryta due to safety concerns.
March 1, 2025:
- First Trial Date Set: A federal judge has scheduled the first trial in the Oxbryta litigation for June 7, 2027. The trial is expected to address whether Pfizer and Global Blood Therapeutics adequately warned about the risk of vaso-occlusive crises (VOCs) for patients taking Oxbryta.
February 4, 2025
- New Oxbryta Study Inconclusive Due to High Dropout Rate: A recent study on Oxbryta published in the journal Blood has raised questions about the drug's efficacy and safety due to a high dropout rate among participants. Over half of the patients in the study either did not start the medication, missed follow-up appointments, or discontinued its use, potentially impacting the reliability of the findings. Despite these limitations, there are rumors that Pfizer may be considering reversing its decision to withdraw Oxbryta from the market.
January 16, 2025
- New Oxbryta Study Raises Questions Due to High Dropout Rate: A recent study published in the journal Blood has raised concerns about the efficacy and safety of Oxbryta, a sickle cell disease drug. The study revealed that over half of the participants did not complete the trial, with many either failing to start the medication, missing follow-up appointments, or discontinuing the drug. This high dropout rate raises questions about the reliability of the study's findings and potentially adds to the ongoing concerns surrounding Oxbryta's effectiveness and safety profile.
December 3, 2024
- Oxbryta Withdrawal Underscores Long-Standing Concerns: Pfizer's recent decision to withdraw Oxbryta from global markets highlights long-held concerns about the drug's safety and effectiveness. Regulatory agencies and health authorities, including the UK's National Institute for Health and Care Excellence (NICE), had previously expressed reservations about Oxbryta's cost-effectiveness and clinical benefits. This withdrawal could strengthen the position of those pursuing lawsuits related to Oxbryta's side effects.
November 19, 2024
- European Regulators Recommend Halting Oxbryta Sales: The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use has recommended suspending the marketing authorization for Oxbryta, a sickle cell disease drug. This decision raises further concerns about the drug's safety profile and could influence regulatory actions in other countries.
November 9, 2024
- New Oxbryta Lawsuit Alleges Increased Health Risks: A new lawsuit filed in California claims that the sickle cell disease drug Oxbryta caused severe health complications, including an increase in vaso-occlusive crises and a stroke. The plaintiff alleges that the manufacturers, Global Blood Therapeutics and Pfizer, failed to adequately warn about these risks despite knowledge of potential adverse effects. The lawsuit seeks damages for various claims, including strict liability, negligence, and breach of warranty.
Oxbryta Linked to Serious Health Risks: File a Lawsuit Today
Oxbryta, a medication for sickle cell disease, has recently been linked to a higher risk of vaso-occlusive crises (VOCs) and other serious health issues. This has led to many patients who took Oxbryta seeking information and legal help.
But you don't have to face this alone. You have rights. At Injury Claims, we connect you with experienced attorneys who will help you understand your legal options and pursue the compensation you deserve if you've been harmed by Oxbryta.
FILL OUT THE FORM FOR MORE INFORMATION
Oxbryta Recall Information
On September 26, 2024, the U.S. Food and Drug Administration (FDA) announced that Pfizer, the manufacturer of Oxbryta, had issued a voluntary recall of the medication.
This recall was initiated due to recent studies that showed an increased risk of VOCs and death in patients taking Oxbryta compared to those taking a placebo.
Oxbryta Use and Increased Health Risks
Studies have shown a possible connection between Oxbryta use and an increased risk of VOCs, a painful and dangerous complication of sickle cell disease. VOCs happen when sickled red blood cells block blood flow, causing severe pain and potentially damaging organs.
The possible link between Oxbryta and these complications raises questions about whether patients were adequately informed of the medication's risks.
What Is a Vaso-Occlusive Crisis (VOC)?
A VOC, also known as a pain crisis, is a common and serious complication of sickle cell disease. It occurs when sickled red blood cells obstruct blood flow to tissues and organs.
Symptoms of a VOC can include:
- Severe pain, often in the bones, chest, and abdomen;
- Swelling in the hands and feet;
- Fever;
- Fatigue; and
- Shortness of breath.
SEE IF YOU QUALIFY FOR AN OXBRYTA LAWSUIT
Symptoms To Watch Out For
If you've been taking Oxbryta, it's important to be aware of the potential symptoms of VOCs and other complications. Seek immediate medical attention if you experience:
- Sudden onset of severe pain,
- Swelling in the hands or feet,
- Fever,
- Difficulty breathing,
- Chest pain, and
- Changes in vision.
Oxbryta Lawsuits
Patients who experienced VOCs, other health problems, or the death of a loved one after taking Oxbryta are taking legal action against the drug's manufacturer.
They claim the manufacturer failed to properly warn about the potential risks. These lawsuits seek to hold the manufacturer responsible and secure compensation for medical costs, lost income, and pain and suffering.
CLICK HERE TO SEE IF YOU QUALIFY TO FILE A CLAIM
